SOUTH SAN FRANCISCO (CBS SF) — A South San Francisco company is developing an Ebola vaccine that can be administered by tablet rather than injection.
Privately-held Vaxart said after a recent meeting with the U.S. Food and Drug Administration it expects to begin human clinical trials of its Ebola vaccine tablet in the first quarter of 2015.READ MORE: UPDATE: Estrada Fire Containment 35%; Evacuation Orders Downgraded as Crews Mop Up
Three other Ebola vaccines are in development by U.S. pharmaceutical firms with testing slated to begin over the next few months, along with a fourth being developed in Russia, but each of those are in injectable form.
Vaxart says its tablet vaccines can be stored at room temperature for more than a year, versus the cold storage needed for injectable vaccines.READ MORE: Hollywood Movie, TV Workers Reach Deal With Producers to Avert Strike
The tablet form of vaccines would offer a significant advantage over injectable versions because it could be distributed and administered in areas with limited infrastructure.
Nearly 5,000 people have died in the Ebola outbreak in west Africa.MORE NEWS: COVID Vaccination Count in San Mateo County Revised Down Due to Data Error
[display-posts tag=”ebola” wrapper=”ul” posts_per_page=”6″]